Voyager Therapeutics Company Profile (NASDAQ:VYGR)

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VYGR
  • CUSIP: N/A
  • Web: www.voyagertherapeutics.com
Capitalization:
  • Market Cap: $229.76 million
  • Outstanding Shares: 26,903,000
Average Prices:
  • 50 Day Moving Avg: $9.08
  • 200 Day Moving Avg: $10.50
  • 52 Week Range: $8.10 - $18.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.30
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.31 million
  • Price / Sales: 27.65
  • Book Value: $4.05 per share
  • Price / Book: 2.11
Profitability:
  • EBIDTA: ($59,320,000.00)
  • Net Margins: -712.22%
  • Return on Equity: -46.15%
  • Return on Assets: -32.66%
Debt:
  • Current Ratio: 12.23%
  • Quick Ratio: 12.23%
Misc:
  • Average Volume: 114,483 shs.
  • Beta: 3.8
  • Short Ratio: 6.77
 

Frequently Asked Questions for Voyager Therapeutics (NASDAQ:VYGR)

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.11. The company earned $1.18 million during the quarter, compared to analyst estimates of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. View Voyager Therapeutics' Earnings History.

Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?

8 brokerages have issued 12-month target prices for Voyager Therapeutics' shares. Their predictions range from $12.00 to $37.00. On average, they expect Voyager Therapeutics' stock price to reach $24.83 in the next twelve months. View Analyst Ratings for Voyager Therapeutics.

What are analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/11/2017)
  • 2. Cowen and Company analysts commented, "VYGR had a 6/30 cash balance of $141MM, sufficient to fund operations into 2019." (8/8/2017)
  • 3. Instinet analysts commented, "We are initiating on Voyager Therapeutics (VYGR) with a Buy rating and $31 target price. We anticipate updates from the ongoing trial of VY-AADC01 confirming efficacy, safety, and framing durability/duration of effect to drive upside in the share price over the next 12 months. In addition, we believe that data and initiation of a pivotal trial in advanced Parkinson's will attract investor attention, as the direct-to-CNS delivery of an enzyme becomes increasingly viewed as a risk-reduced approach to gene therapy with a rapidly addressable $1.5bn DBS-like market opportunity in advanced PD." (3/1/2017)

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:

  • Mark J. Levin, Independent Chairman of the Board
  • Steven M. Paul M.D., President, Chief Executive Officer, Director
  • Jane Pritchett Henderson, Chief Financial Officer, Senior Vice President
  • Robert G. Pietrusko, Senior Vice President - Regulatory Affairs
  • Dinah Sah Ph.D., Chief Scientific Officer
  • Kathleen Hayes, Vice President - Human Resources
  • John J. Connelly, Vice President - Program and Alliance Management
  • Bernard Ravina M.D., Chief Medical Officer
  • Glenn F. Pierce M.D., Ph.D., Director
  • Wendy L. Dixon Ph.D., Independent Director

Who owns Voyager Therapeutics stock?

Voyager Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.01%), Bain Capital Public Equity Management LLC (4.37%), Vanguard Group Inc. (1.60%), DAFNA Capital Management LLC (0.76%), State Street Corp (0.69%) and Northern Trust Corp (0.50%). View Institutional Ownership Trends for Voyager Therapeutics.

Who sold Voyager Therapeutics stock? Who is selling Voyager Therapeutics stock?

Voyager Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC and New York State Common Retirement Fund. View Insider Buying and Selling for Voyager Therapeutics.

Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?

Voyager Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Dimensional Fund Advisors LP, HarbourVest Partners LLC, Northern Trust Corp, Bessemer Group Inc., State Street Corp, Oppenheimer & Co. Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy Voyager Therapeutics stock?

Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of Voyager Therapeutics stock can currently be purchased for approximately $8.54.


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $24.83 (190.79% upside)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
8/8/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
7/28/2017Stifel NicolausInitiated CoverageBuy$20.00HighView Rating Details
5/10/2017WedbushReiterated RatingOutperform$36.00MediumView Rating Details
3/16/2017Chardan CapitalReiterated RatingNeutral -> Neutral$13.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/AView Rating Details
5/20/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Voyager Therapeutics (NASDAQ:VYGR)
Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Earnings History by Quarter for Voyager Therapeutics (NASDAQ VYGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.62)($0.73)$3.27 million$1.18 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
2017 EPS Consensus Estimate: ($2.69)
2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.78)($0.78)($0.78)
Q4 20171($0.85)($0.85)($0.85)
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.73)($0.73)($0.73)
Q3 20181($0.62)($0.62)($0.62)
Q4 20181($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Voyager Therapeutics (NASDAQ:VYGR)
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 41.36%
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Voyager Therapeutics (NASDAQ:VYGR)
Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
Source:
DateHeadline
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 5:40 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 12 at 5:02 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 11 at 4:00 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Voyager Therapeutics, Inc. Decreased by Wedbush (VYGR)
www.americanbankingnews.com - August 11 at 7:48 AM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 9:34 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Announces Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - August 9 at 2:34 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - August 9 at 12:38 AM
finance.yahoo.com logoVoyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - August 8 at 8:15 AM
finance.yahoo.com logoVoyager Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 8:15 AM
feeds.benzinga.com logoVoyager Therapeutics to Host Second Quarter 2017 Financial Results and Corporate Highlights Conference Call
feeds.benzinga.com - August 2 at 12:38 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:22 AM
americanbankingnews.com logoComparing Voyager Therapeutics (VYGR) & Codexis (CDXS)
www.americanbankingnews.com - July 30 at 6:24 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Research Coverage Started at Stifel Nicolaus
www.americanbankingnews.com - July 28 at 9:06 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 18 at 5:03 PM
nasdaq.com logoVoyager Therapeutics Announces Publication from the California Institute of Technology of a Second-
www.nasdaq.com - July 17 at 11:30 AM
finance.yahoo.com logoVoyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain
finance.yahoo.com - July 17 at 11:30 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - July 13 at 10:20 PM
americanbankingnews.com logoZacks Investment Research Lowers Voyager Therapeutics, Inc. (NASDAQ:VYGR) to Sell
www.americanbankingnews.com - July 13 at 10:23 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Quarterly Sales of $3.24 Million
www.americanbankingnews.com - June 28 at 9:51 AM
americanbankingnews.com logo-$0.63 EPS Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter
www.americanbankingnews.com - June 26 at 8:38 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Reports Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
www.streetinsider.com - June 26 at 9:31 AM
finance.yahoo.com logoVoyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
finance.yahoo.com - June 26 at 9:31 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 2:50 PM
finance.yahoo.com logoETFs with exposure to Voyager Therapeutics, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 9:13 AM
finance.yahoo.com logoETFs with exposure to Voyager Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 6 at 1:53 AM
americanbankingnews.com logo$3.24 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - June 2 at 1:10 PM
finance.yahoo.com logoVoyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
finance.yahoo.com - June 2 at 6:02 AM
americanbankingnews.com logo-$0.63 Earnings Per Share Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - May 31 at 4:22 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 2:58 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 17 at 9:38 AM
americanbankingnews.com logoWedbush Weighs in on Voyager Therapeutics Inc's Q2 2017 Earnings (VYGR)
www.americanbankingnews.com - May 12 at 7:52 AM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 9-May-17 9:30pm GMT
finance.yahoo.com - May 11 at 3:20 AM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 10 at 5:18 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - May 10 at 4:38 PM
marketbeat.com logoVoyager Therapeutics reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:24 AM
americanbankingnews.com logoZacks: Brokerages Expect Voyager Therapeutics Inc (VYGR) to Post -$0.54 Earnings Per Share
www.americanbankingnews.com - May 5 at 4:19 PM
finance.yahoo.com logoVoyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - May 5 at 3:36 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Earns Daily Media Impact Rating of -0.03
www.americanbankingnews.com - May 3 at 12:37 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 4:32 PM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receives Daily Coverage Optimism Rating of 0.17
www.americanbankingnews.com - April 30 at 8:52 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receiving Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 26 at 8:29 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Reports Additional Results from Phase 1b Trial of VY-AADC01
www.streetinsider.com - April 25 at 7:33 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Lowered to D+ at TheStreet
www.americanbankingnews.com - April 25 at 4:42 PM
finance.yahoo.com logoVoyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
finance.yahoo.com - April 25 at 8:44 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receives Daily News Impact Rating of -0.22
www.americanbankingnews.com - April 23 at 11:03 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Given News Sentiment Score of 0.15
www.americanbankingnews.com - April 20 at 3:04 PM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receiving Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 16 at 9:50 AM
americanbankingnews.com logo$3.7 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - April 16 at 8:26 AM
americanbankingnews.com logoShort Interest in Voyager Therapeutics Inc (VYGR) Expands By 4.8%
www.americanbankingnews.com - April 15 at 5:56 PM

Social

Chart

Voyager Therapeutics (VYGR) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff